BOARD OF DIRECTORS

  • Kenneth Bate

    Independent Director
    Kenneth Bate has served as a member of our board of directors since January 2014 and as Chairman since February 2016. Mr. Bate is currently an independent consultant. From May 2009 until January 2012, Mr. Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr. Bate was President and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr. Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From January 2005 to March 2006, Mr. Bate was employed at JSB-Partners, a firm that he co-founded. From 2002 to January 2005, Mr. Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Mr. Bate has served as a member of the Board of Directors of Cubist Pharmaceuticals, Inc., a public biopharmaceutical company, since June 2003 and as its non-executive Chair since March 2011. Mr. Bate is a director of five other public biopharmaceutical companies, AVEO Pharmaceuticals, Inc., Epizyme Pharmaceuticals, Inc., Genocea Biosciences, Inc., Vanda Pharmaceuticals, Inc., and TransMedics, Inc. During the last five years, Mr. Bate also served as a director of NitroMed, BioMarin and Coley Pharmaceutical Group, a biopharmaceutical company, which was a public company during the period of Mr. Bate’s service. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe Mr. Bate’s qualifications to serve on our board of directors include his operating, finance, commercial, transactional and senior management experience in the industry, as well as his experience serving on the boards of directors of other public companies in the life sciences industry.
    Financial Expert
  • Burt Adelman, M.D.

    Independent Director
    Burt Adelman, M.D., has served as a member of our board of directors since April 2016. Dr. Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax Corp., or Dyax, a biotechnology company, from February 2012 until its acquisition by Shire Plc in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, Inc., a biotechnology company, where he served as interim President of Research and Development from 2009 to 2010 and as Senior Advisor from February 2011 until December 2011. As Senior Advisor, Dr. Adelman consulted with Eleven Management to ensure a successful leadership transition. From 1991 to 2007, Dr. Adelman held positions of increasing responsibility at Biogen Inc. (formerly Biogen Idec Inc.), a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. Since 1998, Dr. Adelman has served as a lecturer in medicine at Harvard Medical School and as an Associate Physician at Brigham and Women’s Hospital. Dr. Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital.
  • Joanne Beck

    Executive Vice Present, Global Pharmaceutical Development and Operations, Celgene
    Joanne T. Beck, Ph.D. has served as a member of our Board of Directors since February 2019. Dr. Beck is currently the Executive Vice President of Pharmaceutical Development and Operations and a member of the Executive Committee at Celgene. From 2012 to 2016, Dr. Beck was Senior Vice President of Pharmaceutical Development at Shire. Prior to Shire she held positions of increasing responsibility in Abbott’s Global Pharmaceutical Operations and was the site head of Abbott Vascular Instruments GmbH. Prior to Abbott, Dr. Beck held positions in Process Development at Genentech and Amgen. Dr. Beck serves on the board of directors for Orchard Therapeutics and the Alliance for Regenerative Medicine. She holds a BA in Chemistry from Lewis and Clark College, a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.  
  • Jean George

    General Partner, Advanced Technology Ventures
    Jean George has served as a member of our board of directors since October 2013. Since February 2002, she has been a Managing Director at Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms. George has served as Managing Director at LSV Capital Management, a venture capital firm. Ms. George currently serves as a member of the board of directors of the public companies Acceleron Pharma and Calithera Biosciences, and previously served as a member of the board of directors of Portola Pharmaceuticals from 2005 to 2013 and Zeltiq Aesthetics, Inc. from 2005 to 2015. Ms. George also serves on the boards of the private companies Hydra Biosciences, Thrasos Innovation and Proteolix, Inc. Ms. George holds a B.S. in Biology from the University of Maine and an M.B.A. from Simmons College Graduate School of Management.
  • Michael Kishbauch

    Independent Director
    Michael Kishbauch has served as a member of our board of directors since April 2016. He has served as a director of Achillion Pharmaceuticals, Inc., or Achillion, a biotechnology company, since July 2004. Mr. Kisbauch has also served as a director of Progenics Pharmaceuticals, Inc., a biopharmaceutical company, since September 2013 and of TetraLogic Pharmaceuticals Corporation, a biopharmaceutical company, since November 2014. Mr. Kishbauch previously served as President and Chief Executive Officer of Achillion from July 2004 until his retirement in September 2013. Prior to that, he founded and served as President and Chief Executive Officer of OraPharma, Inc., a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson & Johnson in 2003, from 1996 to 2004. Mr. Kishbauch also held senior management positions with MedImmune, Inc., a biotechnology company, from 1992 to 1995. Mr. Kishbauch holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.
    Financial Expert
  • Gregg Lapointe

    Chief Executive Officer, Cerium Pharmaceuticals
    Gregg Lapointe has served as a member of our Board of Directors since January 2019. Since 2012, Mr. Lapointe has served as Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, a privately-held biopharmaceutical company. He previously held varying roles at Sigma-Tau Pharmaceuticals, Inc., a privately held biopharmaceutical company, from 2001 through 2012, including Chief Operating Officer from 2003 to 2008 and Chief Executive Officer from 2008 to 2012. From 1996 to 2001, Mr. Lapointe served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Mr. Lapointe previously served as a member of the Board of Directors of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Pharmaceutical Research Manufacturers of America (PhRMA), and Questcor Pharmaceuticals, Inc. He currently serves on the Board of Directors of three public biopharmaceutical companies, Soligenix, Inc., Cytori Therapeutics, Inc., and Rigel Pharmaceuticals, Inc. He holds an MBA from Duke University, is a Certified Public Accountant, and holds a Bachelor of Commerce from Concordia University. 
  • Jill Milne, Ph.D.

    Co-Founder and Chief Executive Officer
      Jill Milne, Ph.D. is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.